Quality assessment of positron emission tomography scans: recommendations for future multicentre trials
暂无分享,去创建一个
P. Lambin | R. Boellaard | H. Groen | O. Hoekstra | W. V. van Elmpt | E. D. de Jong | E. Smit | A. Dingemans | W. van Elmpt
[1] Paul Kinahan,et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] W. Oyen,et al. Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer , 2007, Journal of Nuclear Medicine.
[3] Ronald Boellaard,et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[4] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[5] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[6] A. Scott,et al. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[7] J. Marcus,et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] R. Wahl,et al. Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey , 2011, The Journal of Nuclear Medicine.
[9] Philippe Lambin,et al. Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.
[10] M. Piccart,et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Andre Dekker,et al. Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer , 2013, Acta oncologica.
[12] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[13] A Sitek,et al. Sensitivity estimation in time-of-flight list-mode positron emission tomography. , 2015, Medical physics.
[14] H. Groen,et al. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] W. Oyen,et al. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Paul Kinahan,et al. Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials , 2015, The Journal of Nuclear Medicine.
[17] R. Boellaard,et al. Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[18] R. Korn,et al. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas† , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Ronald Boellaard,et al. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[20] Philippe Lambin,et al. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures , 2017, The British journal of radiology.
[21] S. Jakobsen,et al. FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach , 2017, Acta oncologica.
[22] S. Jakobsen,et al. Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity , 2017, Acta oncologica.
[23] Anne Bol,et al. Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy , 2017, Acta oncologica.